vaccino.net
Vaccino.net - Informazioni e discussioni su vaccini e vaccinazioni
Vaccino contro la meningite. Vaccino contro il morbillo. Vaccino contro la rosolia. Vaccino contro la varicella. Vaccino contro il papillomavirus. Mancata vaccinazione e aumento delle infezioni. Vaccini e allergia all’uovo. Informazioni e discussioni su vaccini e vaccinazioni. Nasce con l’intento di contribuire alla corretta informazione riguardo vaccini e vaccinazioni. Per farlo abbiamo realizzato, innanzitutto, una semplice e concisa panoramica. Ebola: infettività, trasmissione e rischi. Giugno 29, 2014.
vaccino.skyrock.com
Vaccino's blog - Blog de Vaccino - Skyrock.com
More options ▼. Subscribe to my blog. VENEZ VOIR MA CHAINE! Http:/ www.youtube.com/channel/UCBnb61WRfEKnBamn528bOTw. ET AUSSI CAR JE SUIS UN DIEU. Created: 01/02/2014 at 10:04 AM. Updated: 01/02/2014 at 10:08 AM. This blog has no articles. Subscribe to my blog! Post to my blog. Here you are free.
vaccinogeninc.com
Vaccinogen Treating Colon Cancer with OncoVAX Immunotherapy
Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Peter Morsing, Ph.D. Jason D. Howard, Ph.D. Earl V. Miller, MBA. Drs Dinand van der Linde, MSc, MA. HC Hoover, Jr., M.D. Andrew L. Tussing. Michael G. Hanna, Jr., Ph.D. Human Monoclonal Antibodies (HuMabs) Program. OncoVax Fact Sheet (PDF). Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 1. Vaccines in Immunotherapy of Cancer: OncoVAX Overview Part 2. Manufacturing - Stage 1. Manufacturing - Stage 2. Manufacturing - Stage 3. Stage III Colon Cancer.
vaccinogeninc.investorroom.com
Investor Welcome - Vaccinogen
Human Monoclonal Antibodies (HuMabs) Program. OncoVAX For Colon Cancer. Stage III Colon Cancer. Additional Potential OncoVAX applications. Human Monoclonal Antibodies (HuMabs) Program. Vaccinogen is a biotechnology company with more than three decades of research into combating cancer by using the body’s own immune system. It is the producer of OncoVAX, an immunotherapy for Stage II colon cancer. May 5, 2015. Vaccinogen Names Co-Founder and CEO Andrew L. Tussing as Chairman of the Board. Feb 24, 2015.